Sharp Therapeutics Corp. News Releases

Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting

Fri, 17 Apr 2026 18:13:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its annual audited consolidated financial statements for the year ended December 31, 2025, and related management discussion and analysis ("MD&A") and annual information form. All dollar figures are in United States dollars, unless otherwise stated. Scott Sneddon, Sharp's Chief Executive Officer, stated: "Our...

Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs

Fri, 10 Apr 2026 17:05:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that following longer-term non-GLP testing the company has decided to advance an alternative compound for its Gaucher and GBA1 Parkinson's programs. The company continues to advance all platform programs including programs for genetic and sporadic forms of neurodegeneration (Progranulin modulators), and a rare...

Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering

Fri, 10 Apr 2026 17:00:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the Fourth Tranche, the...

Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering

Thu, 02 Apr 2026 17:43:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the third tranche (the "Third Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the Third Tranche, the Company...

Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering

Fri, 13 Mar 2026 17:05:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the Second Tranche, the...

Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering

Fri, 27 Feb 2026 17:21:00 -0500

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the First Tranche, the...

Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes

Mon, 02 Feb 2026 12:10:00 -0500

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms of a proposed non-brokered private placement for an aggregate principal amount of up to US$3.0 million of unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). The Company anticipates that the initial closing of the...

Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options

Fri, 19 Dec 2025 17:05:00 -0500

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - December 19, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that the non-brokered private placement to raise gross proceeds of not less than US$10,000,000 (the "Offering") previously announced on October 14, 2025 has been updated. The placement will consist of common shares in the capital of the Company priced at not less than US$2.50 per share. The Company expects...

Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update

Wed, 26 Nov 2025 07:35:00 -0500

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its condensed interim consolidated financial statements for the three and nine months ended September 30, 2025, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated.Scott Sneddon, Sharp's Chief Executive Officer, stated: "Our Q3 financial...

Sharp Therapeutics Arranges Non-Brokered Private Placement

Tue, 14 Oct 2025 11:22:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that it is arranging a non-brokered private placement to raise gross proceeds of not less than US$10,000,000 (the "Offering"). The placement will consist of common shares in the capital of the Company priced at not less than US$2.50 per share. The Company expects the offering to close in the fourth quarter of...